Berthon Celine, Nudel Morgane, Boyle Eileen M, Goursaud Laure, Boyer Thomas, Marceau Alice, Quesnel Bruno
CHU Lille, Service des Maladies du Sang, F-59000 Lille, FRANCE.
CNRS, Inserm, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE.
Leuk Res Rep. 2020 Apr 23;13:100202. doi: 10.1016/j.lrr.2020.100202. eCollection 2020.
Synchronous diagnosis of acute myeloid leukemia (AML) and symptomatic multiple myeloma (MM) is a rare situation that poses serious therapeutic difficulties. We report the case of a 68-year-old male which evolved simultaneously to symptomatic MM and AML. Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide. MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival. Little myeloid clonal size reduction over time was seen. This case shows that AML and MM can be effectively treated simultaneously using appropriate combinations.
急性髓系白血病(AML)与有症状的多发性骨髓瘤(MM)的同步诊断是一种罕见情况,会带来严重的治疗困难。我们报告了一例68岁男性患者,其同时进展为有症状的MM和AML。两种疾病在阿扎胞苷 + 来那度胺进行7 + 3诱导和维持治疗后最初对治疗有反应达40个月。MM首先复发,接受了阿扎胞苷 + 达雷妥尤单抗治疗,这带来了额外15个月的无进展生存期。随时间推移可见髓系克隆大小仅有少量减小。该病例表明,使用适当的联合方案可有效同时治疗AML和MM。